《大行》花旗:三生制药(01530.HK)与辉瑞就SSGJ-707达成合作 目标价大升至21元

阿斯达克财经
May 20, 2025

花旗表示,三生制药(01530.HK) 及其子公司沈阳三生宣布与辉瑞(PFE.US)  就其突破性PD-1/VEGF双特异性抗体(SSGJ-707)达成全球(不包括中国)的许可转让合作;三生制药将获得:1)12.5亿美元的预付款;2)高达48亿美元的潜在里程碑付款;3)产品净销售额的阶梯式双位数百分比特许权使用费。花旗认为,此交易的进展和交易对价均超出市场预期。全球扩张是创新制药/生物技术公司的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10